True Wealth Design’s Akebia Therapeutics AKBA Stock Holding History

True Wealth Design’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$811	Buy	711 +665	+1,446%	+$792	﹤0.01%	2059
2026 Q1	$64	Buy	+46	New	+$63	﹤0.01%	2532
2025 Q4	–	Sell	-58	Closed	-$159	–	2564
2025 Q3	$159	Hold	58	–	–	﹤0.01%	2356
2025 Q2	$212	Buy	58 +21	+57%	+$58	﹤0.01%	2054
2025 Q1	$72	Buy	+37	New	+$76	﹤0.01%	2295

Other funds holding AKBA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

IWN

Independent Wealth Network Urbandale, Iowa $393M AUM 30.08% 1-Year Est. Return

LPT

Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return

JWCA

J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return

EWS

Eagle Wealth Strategies West Deptford, New Jersey $262M AUM 31.52% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

True Wealth Design's AKBA Position: Q2 2026 in Review

True Wealth Design increased its Akebia Therapeutics (AKBA) stake by 1,446% in Q2 2026, buying an estimated $792 and bringing the position to 711 shares worth $811. The position accounts for ﹤0.01% of the portfolio, ranked #2059.

True Wealth Design first reported a position in AKBA in Q1 2025 and has held it in 5 quarters since. 15 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

True Wealth Design held 711 shares of Akebia Therapeutics worth $811 as of Q2 2026.
True Wealth Design bought 665 Akebia Therapeutics shares in Q2 2026, an estimated $792.
Akebia Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2059 holding.
True Wealth Design first reported a position in Akebia Therapeutics in Q1 2025 and has held it in 5 quarters since.
15 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.